Logo image of MYTE

MYT NETHERLANDS PARENT BV (MYTE) Stock Fundamental Analysis

NYSE:MYTE - New York Stock Exchange, Inc. - US55406W1036 - ADR - Currency: USD

7.64  -0.2 (-2.55%)

Fundamental Rating

3

MYTE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 121 industry peers in the Specialty Retail industry. MYTE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, MYTE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MYTE had positive earnings in the past year.
In the past year MYTE has reported a negative cash flow from operations.
MYTE had negative earnings in 4 of the past 5 years.
In multiple years MYTE reported negative operating cash flow during the last 5 years.
MYTE Yearly Net Income VS EBIT VS OCF VS FCFMYTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

1.2 Ratios

MYTE has a worse Return On Assets (-5.01%) than 68.85% of its industry peers.
Looking at the Return On Equity, with a value of -8.64%, MYTE is in line with its industry, outperforming 42.62% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 0.05%, MYTE is doing worse than 63.93% of the companies in the same industry.
Industry RankSector Rank
ROA -5.01%
ROE -8.64%
ROIC 0.05%
ROA(3y)-2.35%
ROA(5y)-2.32%
ROE(3y)-3.64%
ROE(5y)-1.89%
ROIC(3y)N/A
ROIC(5y)N/A
MYTE Yearly ROA, ROE, ROICMYTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 5 -5

1.3 Margins

With a Operating Margin value of 0.03%, MYTE is not doing good in the industry: 63.93% of the companies in the same industry are doing better.
MYTE's Gross Margin of 47.04% is fine compared to the rest of the industry. MYTE outperforms 72.13% of its industry peers.
MYTE's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.03%
PM (TTM) N/A
GM 47.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y-0.15%
MYTE Yearly Profit, Operating, Gross MarginsMYTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MYTE is destroying value.
MYTE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MYTE has been reduced compared to 5 years ago.
The debt/assets ratio for MYTE has been reduced compared to a year ago.
MYTE Yearly Shares OutstandingMYTE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MYTE Yearly Total Debt VS Total AssetsMYTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

MYTE has an Altman-Z score of 4.23. This indicates that MYTE is financially healthy and has little risk of bankruptcy at the moment.
MYTE has a Altman-Z score of 4.23. This is amongst the best in the industry. MYTE outperforms 86.07% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that MYTE is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.19, MYTE is doing good in the industry, outperforming 61.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 4.23
ROIC/WACC0.01
WACC7.41%
MYTE Yearly LT Debt VS Equity VS FCFMYTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

MYTE has a Current Ratio of 1.78. This is a normal value and indicates that MYTE is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of MYTE (1.78) is better than 76.23% of its industry peers.
A Quick Ratio of 0.22 indicates that MYTE may have some problems paying its short term obligations.
The Quick ratio of MYTE (0.22) is worse than 85.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 0.22
MYTE Yearly Current Assets VS Current LiabilitesMYTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 525.00% over the past year.
MYTE shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.84%.
The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)525%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)11.84%
Revenue growth 3Y11.16%
Revenue growth 5Y17.27%
Sales Q2Q%13.17%

3.2 Future

The Earnings Per Share is expected to grow by 54.63% on average over the next years. This is a very strong growth
Based on estimates for the next years, MYTE will show a quite strong growth in Revenue. The Revenue will grow by 9.58% on average per year.
EPS Next Y291%
EPS Next 2Y115.23%
EPS Next 3Y54.63%
EPS Next 5YN/A
Revenue Next Year9.06%
Revenue Next 2Y9.71%
Revenue Next 3Y9.58%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MYTE Yearly Revenue VS EstimatesMYTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
MYTE Yearly EPS VS EstimatesMYTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 27.29, which means the current valuation is very expensive for MYTE.
MYTE's Price/Earnings is on the same level as the industry average.
MYTE is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
MYTE is valuated rather expensively with a Price/Forward Earnings ratio of 18.32.
MYTE's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. MYTE is cheaper than 61.48% of the companies in the same industry.
MYTE's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.76.
Industry RankSector Rank
PE 27.29
Fwd PE 18.32
MYTE Price Earnings VS Forward Price EarningsMYTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

67.21% of the companies in the same industry are cheaper than MYTE, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 49.69
MYTE Per share dataMYTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

MYTE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MYTE's earnings are expected to grow with 54.63% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y115.23%
EPS Next 3Y54.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYTE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYT NETHERLANDS PARENT BV

NYSE:MYTE (4/30/2025, 8:23:38 PM)

7.64

-0.2 (-2.55%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)02-11 2025-02-11/bmo
Earnings (Next)05-14 2025-05-14/bmo
Inst OwnersN/A
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.04B
Analysts76.36
Price Target10.71 (40.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)151.51%
Min EPS beat(2)96.08%
Max EPS beat(2)206.95%
EPS beat(4)2
Avg EPS beat(4)50.27%
Min EPS beat(4)-50.98%
Max EPS beat(4)206.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.32%
Min Revenue beat(2)-3.03%
Max Revenue beat(2)0.39%
Revenue beat(4)1
Avg Revenue beat(4)-1.89%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)0.39%
Revenue beat(8)3
Avg Revenue beat(8)-0.99%
Revenue beat(12)4
Avg Revenue beat(12)-1.89%
Revenue beat(16)7
Avg Revenue beat(16)-0.73%
PT rev (1m)0%
PT rev (3m)49.57%
EPS NQ rev (1m)-140.01%
EPS NQ rev (3m)-111.77%
EPS NY rev (1m)0%
EPS NY rev (3m)17.95%
Revenue NQ rev (1m)-0.36%
Revenue NQ rev (3m)-1.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.97%
Valuation
Industry RankSector Rank
PE 27.29
Fwd PE 18.32
P/S 1.05
P/FCF N/A
P/OCF N/A
P/B 2.23
P/tB 3.57
EV/EBITDA 49.69
EPS(TTM)0.28
EY3.66%
EPS(NY)0.42
Fwd EY5.46%
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS7.27
BVpS3.42
TBVpS2.14
PEG (NY)0.09
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.01%
ROE -8.64%
ROCE 0.06%
ROIC 0.05%
ROICexc 0.05%
ROICexgc 0.07%
OM 0.03%
PM (TTM) N/A
GM 47.04%
FCFM N/A
ROA(3y)-2.35%
ROA(5y)-2.32%
ROE(3y)-3.64%
ROE(5y)-1.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y-0.15%
F-Score3
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA 4.11
Cap/Depr 47.13%
Cap/Sales 1.02%
Interest Coverage 0.05
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 0.22
Altman-Z 4.23
F-Score3
WACC7.41%
ROIC/WACC0.01
Cap/Depr(3y)134.72%
Cap/Depr(5y)94.09%
Cap/Sales(3y)2.03%
Cap/Sales(5y)1.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)525%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y291%
EPS Next 2Y115.23%
EPS Next 3Y54.63%
EPS Next 5YN/A
Revenue 1Y (TTM)11.84%
Revenue growth 3Y11.16%
Revenue growth 5Y17.27%
Sales Q2Q%13.17%
Revenue Next Year9.06%
Revenue Next 2Y9.71%
Revenue Next 3Y9.58%
Revenue Next 5YN/A
EBIT growth 1Y101.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year188.35%
EBIT Next 3Y67.88%
EBIT Next 5YN/A
FCF growth 1Y18.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-407.95%
OCF growth 3YN/A
OCF growth 5Y33.41%